Key result
Indomethacin unexpectedly increases hypoxic cerebral vasodilation vs placebo in young adults with metabolic syndrome.
Why the study?
Younger adults with metabolic syndrome exhibit impaired hypoxic cerebral vasodilation, but the mechanisms behind this reduction are unknown.
Does cyclooxygenase inhibition with indomethacin improve hypoxia-mediated cerebral vasodilation in young adults with metabolic syndrome?
RCT (n=28)
double-blind
randomized
Does cyclooxygenase inhibition with indomethacin improve hypoxia-mediated cerebral vasodilation in young adults with metabolic syndrome?
p-value: p=< 0.05
In young adults with metabolic syndrome, increased production of vasoconstrictor prostaglandins restrains hypoxic cerebral vasodilation, a deficit that can be reversed with cyclooxygenase inhibition.
No takes yet. Share an insight, caveat, or question.
Indomethacin may restore hypoxic cerebral vasodilation in metabolic syndrome; extends evidence for vasoconstrictor prostaglandin restraint in this population.
Harrell et al. (2013) conducted an RCT in Metabolic syndrome (n=28). Indomethacin vs. Placebo was evaluated on Hypoxic cerebral vasodilation (cerebrovascular conductance index) (p=< 0.05). Cyclooxygenase inhibition with 100 mg indomethacin unexpectedly increased hypoxic cerebral vasodilation in young adults with metabolic syndrome (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: